This document provides information on Humira (adalimumab), including:
- It is a fully human monoclonal antibody that binds to tumor necrosis factor alpha (TNFα) to reduce inflammation.
- It is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis.
- It is administered via subcutaneous injection usually every other week. Common side effects include infections and allergic reactions.
Significance and Importance of Kava kava as a nutraceuticalPHARMA IQ EDUCATION
1. Introduction
2. Phytochemical constituents
3. Uses of Kava-kava
4. Specific use of a few phytoconstituents of Kava kava
5. Other uses of Kava kava
6. Marketed Formulations
7. Dosing & Side effects
8. Drug interactions
9. References
10. Thanks you
Anticancer Drug, also called Anti-Neoplastic drug, that is effective in the treatment of malignant, or cancerous, disease. There are several major classes of anticancer drugs; these include Alkylating Agents, Anti-metabolites, Plant Alkaloids and Hormones.
Immunosuppressants are drugs or medicines that lower the body's ability to reject a transplanted organ. Another term for these drugs is anti-rejection drugs. There are 2 types of immunosuppressants:
Induction drugs: Powerful antirejection medicine used at the time of transplant
Maintenance drugs: Antirejection medications used for the long term.
Artemisinin(qinghaosu), is a drug used for treatment of malaria. It is extracted from the Chinese herb Artemisia annua.
It has three major derivatives— Artemether, Artesunate and Dihydroartemisinin
Significance and Importance of Kava kava as a nutraceuticalPHARMA IQ EDUCATION
1. Introduction
2. Phytochemical constituents
3. Uses of Kava-kava
4. Specific use of a few phytoconstituents of Kava kava
5. Other uses of Kava kava
6. Marketed Formulations
7. Dosing & Side effects
8. Drug interactions
9. References
10. Thanks you
Anticancer Drug, also called Anti-Neoplastic drug, that is effective in the treatment of malignant, or cancerous, disease. There are several major classes of anticancer drugs; these include Alkylating Agents, Anti-metabolites, Plant Alkaloids and Hormones.
Immunosuppressants are drugs or medicines that lower the body's ability to reject a transplanted organ. Another term for these drugs is anti-rejection drugs. There are 2 types of immunosuppressants:
Induction drugs: Powerful antirejection medicine used at the time of transplant
Maintenance drugs: Antirejection medications used for the long term.
Artemisinin(qinghaosu), is a drug used for treatment of malaria. It is extracted from the Chinese herb Artemisia annua.
It has three major derivatives— Artemether, Artesunate and Dihydroartemisinin
3d Stock Charts - Life 2.0 Data Visualization PanelMelanie Swan
So far virtual worlds have been used mainly for architectural builds and interaction. The next obvious step is making them alive with data, streaming in data and representing it visually. Data visualization in Second Life is growing rapidly.
Wiki: http://sldataviz.pbwiki.com/
Conference link: http://www.life20.net
Large Molecule Bioanalysis: LC-MS or ELISA? A Case StudyQPS Holdings, LLC
Both ligand binding assays (LBA) and mass spectrometry
(MS) methods are widely used in routine bionalysis with expanded applications of MS to large molecules in
the years ahead. In this presentation, PK parameters in the rart for three monoclonal antibodies (mAbs) are compared as derived from plasma concentration data as measured by LBA or Immunocapture LC-MS/MS.
TNO Triskelion BSL-3 lab tests anti-viral drugs in newly developed H7N9 influenza model
Human infections with a new avian influenza A (H7N9) virus were first reported in China in 2013, with the loss of 46 lives. In order to meet the growing needs to test new drugs against H7N9, TNO Triskelion has recently developed an H7N9 mouse model. This H7N9 model is suitable for testing new anti-virals such as vaccines, monoclonal antibodies and small molecules in our BSL-3 lab, in conformity with Good Laboratory Practice. TNO Triskelion has proven to be a successful partner in the development of new anti-viral and anti-bacterial vaccines for many years. Understanding the pressures on time lines, we support companies and institutes during the preclinical and clinical stages of drug development.
Increasing knowledge of genetics and cell processes leads to potential new biologic (and drug) targets at each step in the protein-production process. This leads to new therapies, which in turn lead to new understanding of diseases. Here is an update on relatively new drugs called biologics...
Synthetic Biology: Bringing Engineering Back Into Genetic EngineeringSachin Rawat
Genetic Engineering lacks a few elements of Engineering. Here is what those are and how Synthetic Biology (or Genetic Engineering v2.0) would account for those.
Establishing other new medical usages for already known drugs, including approved drugs.
Drug repurposing lies in repurposing an active pharmaceutical ingredient for a new indication that is already on the market.
Drug repurposing is a promising approach and mainly applied for the treatment of both common and rare genetic diseases, and it also offers significant benefits to the pharmaceutical industries.
"At its simplest, drug repurposing is taking an existing drug and seeing whether it can be used as an effective treatment for another condition.“
“Repurposing generally refers to studying drugs that are already approved to treat one disease or condition to see if they are safe and effective for treating other diseases”.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
4. Introduction
• Humira stands for :human monoclonal anti
body in rheumatoid arthritis .
• Human monoclonal antibody against TNF-
alpha.
• C6428H9912N1694O1987S46.
5. Introduction
• It binds to (TNFα), which normally binds to
TNFα receptors, leading to the
inflammatory response of autoimmune
diseases. By binding to TNFα, adalimumab
reduces this inflammatory response.
• Humira costs approximately $3,100 per
month, From 2012 to US patent expiry in
2016, Humira led the list of top-selling
pharmaceutical products, and in 2016, it
had $16 billion of global sales.
6. Introduction
History
• Adalimumab was the first fully human
monoclonal antibody approved by the
U.S. Food and Drug administration.
• Engineered through guided
selection techniques phage display
and was discovered through a
collaboration between BASF
Bioresearch Corporation and
Cambridge Antibody Technology.
• Initially named D2E7.
11. Mechanism of action
• directly binding to TNF- α molecules in the
blood and diseased tissue.
• blocks its interaction with the p55 and p75 cell
surface TNF receptors.
• lyses surface TNF expressing cells in vitro.
• does not bind or inactivate lymphotoxin (TNF-
beta).
• Adalimumab helps to stop the inflammatory
cycle of psoriatic disease and prevent from
causing the inflammation that result in
psoriasis plaques.
12. TNF
SIGNAL
Monoclonal Antibody directed against
TNF-alpha: Infliximab (Remicade ®),
Adalimumab (Humira®)
Soluble TNF-Receptors serve as a
balance to TNF
Engineered Soluble TNF Receptor
(Enbrel®)
13.
14.
15. Uses
• Rheumatoid arthritis
• Adalimumab has been shown to
reduce the signs and symptoms of
moderate to severe rheumatoid
arthritis (RA) in adults. it has been
approved for use alone, or with
methotrexate or similar medicines,
in the U.S. since 2002.
16. Uses
• Psoriatic arthritis
• In 2003, adalimumab began
undergoing trials for use in treating
psoriasis and psoriatic arthritis.
• Ankylosing spondylitis
• Adalimumab has been shown to
reduce the signs and symptoms
and is approved for treatment of,
ankylosing spondylitis in adults.
17. Uses
• Crohn’s disease
Adalimumab has been shown to reduce the
signs and symptoms of moderate to severe
Crohn's disease. It has been approved for that
use in the UK since 2009.
• Ulcerative colitis
Adalimumab may be effective and well
tolerated in ulcerative colitis. It has been
approved by the FDA for treatment of
moderate to severe cases in adults.
18. Uses
• Plaque psoriasis
Adalimumab has been shown to treat moderate to severe chronic plaque
psoriasis in adults who have the condition in many areas of their body
Adalimumab has been shown to be effective therapy when used either
continuously or intermittently in patients with moderate to severe psoriasis.
• Juvenile idiopathic arthritis
Humira in combination with methotrexate is indicated for the treatment of
active polyarticular juvenile idiopathic arthritis, in patients from the age of 2
years who have had an inadequate response to one or more disease-
modifying anti-rheumatic drugs (DMARDs). Humira can be given as
monotherapy in case of intolerance to methotrexate or when continued
treatment with methotrexate is inappropriate it has-been shown to reduce
the signs and symptoms of moderate to severe polyarticular juvenile
idiopathic arthritis in children 4 and older.
19.
20.
21.
22. How to use ?
• Adalimumab is administered by
subcutaneous injection For most
indications, the maintenance
treatment is an injection every other
week.
23.
24.
25.
26. Side effects
• Upper respiratory tract infection and
asthma like symptoms, latent infections
such as tuberculosis can be reactivated,
and the immune system may be unable to
fight new infections. This has led to fatal
infections in some patients.
• Hepatitis B reactivation , people who
develop HBV reactivation should stop
Humira and effective anti-viral therapy
with appropriate supportive treatment
should be initiated.
27. Side effects
• Allergic reactions that might lead to Anaphylaxis
or other serious allergic reactions may also occur.
• Immunosuppression the immune system may be
unable to fight new infections. This has led to fatal
infections in some patients.
• Malignancies and lymphoproliferative disorders In
the controlled portions of clinical trials of TNF-
antagonists, more cases of malignancies including
lymphoma have been observed among patients
receiving a TNF-antagonist compared with control
patients. However, the occurrence was rare
28.
29. Advantages vs. disadvantages
• Humira (Adalimumab) Advantages:
• Humira (Adalimumab) is injected on the surface of
the body thus hastening it’s absorption into the
body.
• Humira (Adalimumab) has a quick turnaround (one
day up to 2 months) as compared to competition.
• Very rapid onset of action.
• Humira (Adalimumab) Disadvantages:
• Humira (Adalimumab) is available on prescription
only.
• You require a skilled person or training to administer
Humira (Adalimumab).
• Costs approximately $3,100 per month.
• Humira (Adalimumab) side effects some that are
fatal.
30.
31. Related drugs
• Infliximab (trade names Remicade among others) is a
chimeric monoclonal antibody biologic drug that
works against tumor necrosis factor alpha (TNF-α).
• Certolizumab pegol (CDP870, trade name Cimzia) is a
biologic medication for the treatment of Crohn's
disease, rheumatoid arthritis, psoriatic arthritis and
ankylosing spondylitis.
• Golimumab (CNTO 148) is a human monoclonal
antibody which is used as an immunosuppressive drug
and marketed under the brand name Simponi.
Golimumab targets tumor necrosis factor alpha (TNF-
alpha), a pro-inflammatory molecule.
32.
33.
34. References
• http://www.aafp.org/afp/2008/1215/p1406.html
• http://www.genengnews.com/the-lists/the-top-15-best-selling-drugs-of-
2016/77900868?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_co
ntent=01&utm_campaign=GEN+Daily+News+Highlights_20170307
• https://www.fda.gov/downloads/drugs/drugsafety/ucm088611.pdf
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines.
Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis
Rheum2002;46:328–46.
• OpenUrlCrossRefPubMedWeb of Science
• Brekke OH; Sandlie I (January 2003). "Therapeutic antibodies for human diseases at the dawn of
the twenty-first century". Nat Rev Drug Discov. 2 (1): 52–62. doi:10.1038/nrd984.
PMID 12509759.
• Kempeni J (January 1999). "Preliminary results of early clinical trials with the fully human anti-
TNFα monoclonal antibody D2E7". Ann Rheum Dis. 58 (suppl 1): I70–2.
doi:10.1136/ard.58.2008.i70. PMC 1766582 . PMID 10577977
• Salfeld J, Kaymakçalan Z, Tracey D, Roberts A, Kamen R. Generation of fully human anti-TNF
antibody D2E7. [Abstract]. Arthritis Rheum1998;41 (suppl):S57.
• https://www.ncbi.nlm.nih.gov/pubmed/12884458
• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936294/pdf/tcrm0301-133.pdf
• http://search.proquest.com/openview/321f9bb2c9a8d759fc250b11063bfd7f/1?pq-
origsite=gscholar&cbl=33668
• https://www.omicsgroup.org/journals/analysis-of-the-mechanism-of-action-of-biological-
therapies-in-monotherapy-in-patients-with-rheumatoid-arthritis-beyond-the-adacta-study-
2167-1052.1000141.pdf
• https://www.youtube.com/watch?v=Evsq3I28eHQ
• Siegel, Jay P., M.D., FACP. "Therapeutic Biologic Applications (BLA) – Humira Approval Letter
35. References
• 12/31/02". Center for Drug Evaluation and Research. Retrieved 2014-02-04.
• "Humira® (Adalimumab) - 2011023-Humira.pdf" (PDF). Retrieved 2014-02-04.
•
• Scheinfeld, N (2003). "Adalimumab (HUMIRA): a review". J Drugs Dermatol. 2 (4): 375–7.
PMID 12884458.
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000481/WC500050870.pdf
• Maxwell, LJ; Zochling, J; Boonen, A; Singh, JA; Veras, MM; Tanjong Ghogomu, E; Benkhalti
Jandu, M; Tugwell, P; Wells, GA (18 April 2015). "TNF-alpha inhibitors for ankylosing
spondylitis.". The Cochrane database of systematic reviews. 4: CD005468.
doi:10.1002/14651858.CD005468.pub2. PMID 25887212.
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000481/WC500050870.pdf
•
• Podolsky, Daniel K. (August 2002). "Inflammatory bowel disease". N Engl J Med. 347 (6): 417–
29. doi:10.1056/NEJMra020831. PMID 12167685
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000481/WC500050870.pdf
•
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000481/WC500050870.pdf
•
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000481/WC500050870.pdf
• Jump up ^ Croom, Katherine F; McCormack, Paul L (2009). "Adalimumab". Am J Clin Dermatol.
10 (1): 43–50. doi:10.2165/0128071-200910010-00008. PMID 19170412
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000481/WC500050870.pdf
• https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/kem356
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000481/WC500050870.pdf
•
36. References
• https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=78456
• Jump up to Humira - Full prescribing information
• https://academic.oup.com/rheumatology/article/44/9/1199/2899286/Adalimumab-
induced-asthma
• Karen M. Frank, et al, Investigation of the cause of death in a gene-therapy trial, N Engl
J Med 361:161, July 9, 2009
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000481/WC500050870.pdf
• http://www.tandfonline.com/doi/abs/10.1517/14740338.4.4.637
• FDA label – http://www.rxabbott.com/pdf/humira_medguide.pdf
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000481/WC500050870.pdf
• Karen M. Frank, et al, Investigation of the cause of death in a gene-therapy trial, N Engl J Med 361:161, July 9,
2009
• http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Product_Information/human/000481/WC500050870.pdf
•
• "Archived copy". Archived from the original on 2011-07-10. Retrieved 2011-03-06
• https://www.ncbi.nlm.nih.gov/pubmed/27924644
• [Official Website for REMICADE® (infliximab) http://www.remicade.com
37. References
• Sandborn WJ, Feagan BG, Stoinov S, et al. (July 2007). "Certolizumab pegol for
the treatment of Crohn's disease". N. Engl. J. Med. 357 (3): 228–38.
doi:10.1056/NEJMoa067594. PMID 17634458.
• Goel, Niti; Sue Stephens (2010). "Certolizumab pegol". MAbs. 2 (2): 137–147.
doi:10.4161/mabs.2.2.11271. PMC 2840232 . PMID 20190560
•
• Mazumdar, Sohini; David Greenwald (2009). "Golimumab". MAbs. 1 (5): 422–
431. doi:10.4161/mabs.1.5.9286.
• Statement On A Nonproprietary Name Adopted By The USAN Council –
Golimumab
•
• Raduner S, Majewska A, Chen JZ, Xie XQ, Hamon J, Faller B, Altmann KH,
Gertsch J (May 2006). "Alkylamides from Echinacea are a new class of
cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent
immunomodulatory effects". J. Biol. Chem. 281 (20): 14192–206.
doi:10.1074/jbc.M601074200. PMID 16547349
• Gulcubuk A, Altunatmaz K, Sonmez K, Haktanir-Yatkin D, Uzun H, Gurel A, Aydin S
(February 2006). "Effects of curcumin on tumour necrosis factor-alpha and
interleukin-6 in the late phase of experimental acute pancreatitis". J Vet Med a
Physiol Pathol Clin Med. 53 (1): 49–54. doi:10.1111/j.1439-0442.2006.00786.x.
PMID 16411910.
• Lantz RC, Chen GJ, Solyom AM, Jolad SD, Timmermann BN (June 2005). "The
effect of turmeric extracts on inflammatory mediator production".
Phytomedicine. 12 (6–7): 445–52. doi:10.1016/j.phymed.2003.12.011.
PMID 16008121